Creative Planning Atara Biotherapeutics, Inc. Transaction History

Creative Planning

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 10, 2023	SELL	$2.85 - $5.18 $4,158 - $7,557	-1,459 Reduced 2.17%	65,659 $215,000
Q3 2022 Nov 03, 2022	BUY	$2.85 - $8.73 $18,211 - $55,784	6,390 Added 10.52%	67,118 $254,000
Q1 2022 May 16, 2022	BUY	$8.44 - $16.89 $512,544 - $1.03 Million	60,728 New	60,728 $564,000
Q1 2020 May 05, 2020	SELL	$5.69 - $17.78 $84,536 - $264,157	-14,857 Closed	0 $0
Q2 2019 Jul 26, 2019	SELL	$19.05 - $41.04 $952 - $2,052	-50 Reduced 0.34%	14,857 $299,000

Q1 2019 Apr 24, 2019	BUY	$28.4 - $41.74 $1,420 - $2,087	50 Added 0.34%	14,907 $593,000
Q4 2018 Feb 01, 2019	SELL	$30.9 - $42.97 $4,974 - $6,918	-161 Reduced 1.07%	14,857 $516,000
Q3 2018 Oct 25, 2018	BUY	$35.05 - $43.5 $36,802 - $45,675	1,050 Added 7.52%	15,018 $621,000
Q2 2018 Jul 20, 2018	BUY	$35.15 - $51.45 $12,689 - $18,573	361 Added 2.65%	13,968 $513,000
Q1 2018 Apr 18, 2018	BUY	$18.0 - $48.35 $244,926 - $657,898	13,607 New	13,607 $531,000

85M

18.4K

51.3K

Ticker ATRA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 94,362,304
Market Cap $728M
Description
Atara Biotherapeutics, Inc., an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. It is developing tabelecleucel, a T-cell immunotherapy that is Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferat...

Get notified when there are updates to the investment portfolio of Creative Planning, based on Form 13F filings with the SEC.

Stay updated on Creative Planning with notifications on news.